心的外傷後ストレス障害:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC10060IDB)
◆英語タイトル:Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2018
◆商品コード:GMDHC10060IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年1月18日
◆ページ数:127
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における心的外傷後ストレス障害の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・心的外傷後ストレス障害の概要
・心的外傷後ストレス障害治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・心的外傷後ストレス障害パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・心的外傷後ストレス障害治療薬開発に取り組んでいる企業:企業別製品パイプライン
・心的外傷後ストレス障害治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2018, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that’s triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) – Overview
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Traumatic Stress Disorder (PTSD) – Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Aptinyx Inc
Azevan Pharmaceuticals Inc
Bionomics Ltd
Catalyst Pharmaceuticals Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Eli Lilly and Co
Embera NeuroTherapeutics Inc
Immodulon Therapeutics Ltd
Johnson & Johnson
Marinus Pharmaceuticals Inc
NeuroNascent Inc
Omeros Corp
Otsuka Holdings Co Ltd
Pragma Therapeutics SAS
SpringWorks Therapeutics LLC
Synchroneuron Inc
Tonix Pharmaceuticals Holding Corp
Post-Traumatic Stress Disorder (PTSD) – Drug Profiles
(metyrapone + oxazepam) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acamprosate calcium SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71743 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3506 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CERC-501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-473 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ganaxolone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-107 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDAC-0001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
midomafetamine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NNI-351 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRX-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRX-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NYX-783 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04457845 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PGT-117 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rycal – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR83 for CNS and Immunological Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR-4 for CNS Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-246 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-601 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for CNS Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZL-006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Post-Traumatic Stress Disorder (PTSD) – Dormant Projects
Post-Traumatic Stress Disorder (PTSD) – Discontinued Products
Post-Traumatic Stress Disorder (PTSD) – Product Development Milestones
Featured News & Press Releases
Jan 03, 2018: Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018
Dec 12, 2017: Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
Dec 07, 2017: Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
Nov 30, 2017: Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
Nov 14, 2017: Aptinyx to Present Preclinical Data for NMDA Receptor Modulator NYX-783 at Neuroscience 2017
Nov 01, 2017: Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
Oct 17, 2017: Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
Oct 12, 2017: Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Sep 29, 2017: Tonix Pharmaceuticals Presented at the 2nd Annual Cohen Veterans Care Summit in Washington, D.C.
Sep 18, 2017: Multidisciplinary Association for Psychedelic Studies (MAPS) Selects Montrium’s eTMF Platform as They Begin Phase 3 Studies of MDMA-assisted Psychotherapy for PTSD
Sep 14, 2017: Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets)
Sep 06, 2017: Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Sep 01, 2017: Bionomics BNC210 to Feature at the 30th ECNP Congress
Aug 29, 2017: Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Aug 26, 2017: FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2018
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

【レポートのキーワード】

心的外傷後ストレス障害

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 心的外傷後ストレス障害:治療薬開発パイプライン分析(Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆